Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Other Pulmonary Disorders
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapy.
Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant Tuberculosis.
Antibiotic pressure does not uncover intra-host heterogeneity of Pseudomonas aeruginosa in patients with chronic lung disease.
Robust antibiotic sensitization of pathogenic Pseudomonas aeruginosa via negative hysteresis in the cell envelope.
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation study.
Correction to Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study Lancet Reg Health Eur 57 (2025) 101416 LLRHEUROPE-D-25-00310.
["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].
[Emergency management of sickle cell disease].
[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]
[Diagnosis of Congenital Hemolytic Anemias in Adults].
[46-year-old female patient with right upper abdominal pain].
Related Experiment Video
Updated: Apr 1, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
[Tuberculosis].
Barbara Kalsdorf1, Ioana D Olaru1, Christoph Lange1
1Klinische Infektiologie, Forschungszentrum Borstel.
Tuberculosis remains a major global health threat. Advances in prevention, diagnosis, and treatment offer new hope, particularly for drug-resistant Mycobacterium tuberculosis strains.
Area of Science:
- Global Health
- Infectious Diseases
- Microbiology
Context:
- Tuberculosis (TB) is a leading cause of death worldwide.
- Drug-resistant Mycobacterium tuberculosis strains pose a significant challenge, especially in Europe.
- Recent progress has been made in TB management.
Purpose:
- To review recent advances in tuberculosis prevention, diagnosis, and treatment.
- To highlight progress in managing multidrug-resistant tuberculosis (MDR-TB).
Summary:
- Significant advancements have been achieved in combating tuberculosis.
- New strategies for TB prevention, diagnosis, and treatment are emerging.
- Effective management of multidrug-resistant tuberculosis (MDR-TB) is improving.
Impact:
- Improved patient outcomes for tuberculosis.
- Potential reduction in tuberculosis morbidity and mortality.
- Enhanced strategies to combat drug-resistant tuberculosis strains globally.

